semaglutide elisa cross-reactivity glp-1 Frontiers Citrate plasma Ecnoglutide vs Semaglutide: Biased GLP-1

Cell Transplant 25(5):849861 Matsuyama N, Shimizu S, Ueda K, Suzuki T, Suzuki S, Miura R, Katayama A, Ando M et al (2022) Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial): a clinical trial protocol open-label, non-randomised, dose-escalation trial

Glucagon receptor signaling and lipid metabolism

Along with diet and exercise changes, Wegovy is approved to lower the risk of major cardiovascular events such as heart attack and stroke in adults who have both cardiovascular disease and excess weight (classified as overweight or with obesity)

This approval came from the SELECT trial, which demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide compared to placebo